Supha Pharmachem
0.36
+0.01(+2.86%)
Market Cap₹31.78 Cr
PE Ratio17.50
Company Performance:
1D+2.86%
1M-47.06%
6M-76.47%
1Y-72.93%
5Y+38.46%
View Company Insightsright
More news about Supha Pharmachem
14Nov 25
Remedium Lifecare Reports Robust Q2 Performance with 85.50% Profit Surge
Remedium Lifecare Limited's Q2 2025 results show significant profit growth. Net profit increased by 85.50% to ₹862.34 lakhs from ₹464.88 lakhs in Q1 2025. Revenue slightly decreased by 2.04% to ₹11,105.82 lakhs. Total expenses reduced, contributing to improved profitability. The company maintains a strong financial position with total assets of ₹1,62,318.10 lakhs and total equity of ₹10,519.86 lakhs.
 no imag found
10Nov 25
Remedium Lifecare Bolsters Board with Two Key Appointments
Remedium Lifecare Ltd. has appointed Vignesh Laxman Gawde as Whole-Time Director and Rambhajan Vishwakarma as Independent Director. Gawde brings 14+ years of pharmaceutical research experience, focusing on R&D and quality assurance. Vishwakarma contributes 15+ years of banking and financial services expertise. These appointments aim to enhance the company's leadership, promote growth, and strengthen its position in the pharmaceutical and specialty chemicals sector.
 no imag found
31Oct 25
Remedium Lifecare Appoints New Directors and Restructures Board Committees
Remedium Lifecare Limited has made significant changes to its board composition and committee structure. The company appointed Mr. Rambhajan Vishwakarma as Additional Director and Chairman, and Mr. Vignesh Laxman Gawde as Additional Executive Director for a five-year term. Both appointments are effective from October 31, 2025, subject to shareholder approval. The company also reconstituted four key committees: Audit, Nomination and Remuneration, Stakeholders Relationship, and Risk Management. A postal ballot has been approved for changing the company name and regularizing the new appointments.
 no imag found
25Aug 25
Remedium Lifecare Unveils 4-Point Strategy for 4X Growth, Reports Strong Q1 Performance
Remedium Lifecare announced a strategic roadmap for 4X growth, focusing on advanced manufacturing, global export expansion, innovation and R&D excellence, and product diversification. The company reported impressive Q1 results with a 327% YoY increase in Profit After Tax to ₹464.88 lakh, surpassing the entire previous fiscal year's PAT. A successful oversubscribed Rights Issue raised ₹47.88 crore. The company aims to upgrade CDMO facilities, enter new markets, establish a quality control laboratory, and broaden its product portfolio in specialty chemicals and pharmaceuticals.
 no imag found
11Aug 25
Remedium Lifecare Reports Stellar Q1 Results, Surpassing Previous Annual Profit
Remedium Lifecare, a pharmaceutical supply chain and specialty chemicals company, has reported outstanding Q1 financial results. The company's Profit After Tax (PAT) reached ₹464.88 lakh, more than doubling its entire previous annual profit. Revenue from Operations stood at ₹11,336.67 lakh, with Profit Before Tax (PBT) at ₹571.23 lakh. This marks a significant turnaround from the previous quarter's loss. The company attributes its success to operational efficiency and prudent financial management. Future plans include expanding R&D focus, building CDMO services, global expansion, and enhancing working capital management.
 no imag found
04Aug 25
Remedium Lifecare Reports Mixed Q1 Results: Consolidated Profit Amidst Standalone Loss
Remedium Lifecare Limited (RLL) announced its Q1 financial results, showing a consolidated profit of ₹4.65 crore despite a standalone loss of ₹36.51 lakh. Consolidated revenue from operations was ₹113.37 crore, while standalone revenue declined to ₹18.37 crore from ₹77.70 crore year-over-year. The subsidiary, Remlife Global PTE, significantly contributed to the group's positive financial outcome. The company's business activity falls within a single segment, and the results were reviewed by the Audit Committee and approved by the Board of Directors.
 no imag found
22Jul 25
Remedium Lifecare Expands Globally with Singapore Subsidiary, Secures ₹182.7 Crore Export Contract
Remedium Lifecare Limited has undertaken several strategic moves to strengthen its global presence. The company established a wholly-owned subsidiary in Singapore, secured a ₹182.70 crore export contract, completed a successful rights issue, formed a partnership with Jia Yu Lifesciences, and enhanced its quality control infrastructure. These initiatives aim to transition Remedium into a full-spectrum pharmaceutical solutions provider, expand its international footprint, and drive long-term growth.
 no imag found
Supha Pharmachem
0.36
+0.01
(+2.86%)
1 Year Returns:-72.93%
Industry Peers
Redington
201.11
(-0.66%)
MMTC
55.36
(+0.33%)
MSTC
407.35
(+4.91%)
Ravindra Energy
132.31
(+2.71%)
BN Agrochem
220.00
(+2.23%)
TCC Concept
350.00
(+1.10%)
Creative Newtech
595.80
(+7.33%)
The Yamuna Syndicate
27,305.00
(+0.01%)